Physician profile

Heather Svenson

Pediatrics · Orange Park, FL

NPI 1649381880

$496.69

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$233.32

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Tris Pharma INC $124.03 2023 Dyanavel Xr, Quillichew Er, Quillivant
Corium, LLC $123.05 2022
Regeneron Healthcare Solutions, INC. $109.81 2022
Pfizer INC. $42.07 2024
Supernus Pharmaceuticals, INC. $29.33 2024 Qelbree
Exact Sciences Corporation $20.03 2023 Cologuard Collection Kit
Bayer Healthcare Pharmaceuticals INC. $17.86 2023
Glaxosmithkline, LLC. $15.71 2022
Adlon Therapeutics L.P. $14.80 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Heather Svenson

$496.69

in general payments reported 2019-2025

Years
2020-2024
Top company
Tris Pharma INC

https://glasscript.com/doctor/1093290/heather-svenson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.